Illumina, Inc. (ILMN)
USD 134.03
(-6.35%)
USD 134.03
(-6.35%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.16 Billion USD | 73.64% |
| 2022 | -4.4 Billion USD | -677.95% |
| 2021 | 762 Million USD | 16.16% |
| 2020 | 656 Million USD | -34.53% |
| 2019 | 1 Billion USD | 21.31% |
| 2018 | 826 Million USD | 13.77% |
| 2017 | 726 Million USD | 56.92% |
| 2016 | 462.64 Million USD | 0.24% |
| 2015 | 461.55 Million USD | 30.62% |
| 2014 | 353.35 Million USD | 181.99% |
| 2013 | 125.3 Million USD | -17.15% |
| 2012 | 151.25 Million USD | 74.6% |
| 2011 | 86.62 Million USD | -30.64% |
| 2010 | 124.89 Million USD | 72.79% |
| 2009 | 72.28 Million USD | 43.2% |
| 2008 | 50.47 Million USD | 118.13% |
| 2007 | -278.35 Million USD | -796.45% |
| 2006 | 39.96 Million USD | 291.47% |
| 2005 | -20.87 Million USD | -235.33% |
| 2004 | -6.22 Million USD | 77.0% |
| 2003 | -27.06 Million USD | 32.9% |
| 2002 | -40.33 Million USD | -62.47% |
| 2001 | -24.82 Million USD | -33.41% |
| 2000 | -18.6 Million USD | -237.22% |
| 1999 | -5.51 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 705 Million USD | 135.46% |
| 2024 Q1 | -126 Million USD | 28.41% |
| 2024 Q2 | -1.98 Billion USD | -1477.78% |
| 2023 Q2 | -234 Million USD | -7900.0% |
| 2023 Q1 | 3 Million USD | 102.14% |
| 2023 FY | -1.16 Billion USD | 73.64% |
| 2023 Q4 | -176 Million USD | 76.66% |
| 2023 Q3 | -754 Million USD | -222.22% |
| 2022 FY | -4.4 Billion USD | -677.95% |
| 2022 Q4 | -140 Million USD | 96.33% |
| 2022 Q3 | -3.81 Billion USD | -613.27% |
| 2022 Q2 | -535 Million USD | -722.09% |
| 2022 Q1 | 86 Million USD | -23.21% |
| 2021 Q1 | 147 Million USD | -42.8% |
| 2021 Q2 | 185 Million USD | 25.85% |
| 2021 Q4 | 112 Million USD | -64.67% |
| 2021 Q3 | 317 Million USD | 71.35% |
| 2021 FY | 762 Million USD | 16.16% |
| 2020 Q3 | 179 Million USD | 280.85% |
| 2020 Q4 | 257 Million USD | 43.58% |
| 2020 FY | 656 Million USD | -34.53% |
| 2020 Q1 | 173 Million USD | -27.62% |
| 2020 Q2 | 47 Million USD | -72.83% |
| 2019 Q4 | 239 Million USD | 2.14% |
| 2019 FY | 1 Billion USD | 21.31% |
| 2019 Q1 | 233 Million USD | 10.95% |
| 2019 Q2 | 296 Million USD | 27.04% |
| 2019 Q3 | 234 Million USD | -20.95% |
| 2018 FY | 826 Million USD | 13.77% |
| 2018 Q1 | 208 Million USD | 205.88% |
| 2018 Q2 | 209 Million USD | 0.48% |
| 2018 Q3 | 199 Million USD | -4.78% |
| 2018 Q4 | 210 Million USD | 5.53% |
| 2017 Q1 | 373 Million USD | 201.38% |
| 2017 FY | 726 Million USD | 56.92% |
| 2017 Q4 | 68 Million USD | -58.28% |
| 2017 Q3 | 163 Million USD | 27.34% |
| 2017 Q2 | 128 Million USD | -65.68% |
| 2016 FY | 462.64 Million USD | 0.24% |
| 2016 Q4 | 123.76 Million USD | -3.98% |
| 2016 Q1 | 89.58 Million USD | -14.25% |
| 2016 Q3 | 128.88 Million USD | 7.04% |
| 2016 Q2 | 120.41 Million USD | 34.41% |
| 2015 Q1 | 136.65 Million USD | -10.84% |
| 2015 Q4 | 104.47 Million USD | -11.59% |
| 2015 Q2 | 102.24 Million USD | -25.18% |
| 2015 Q3 | 118.17 Million USD | 15.58% |
| 2015 FY | 461.55 Million USD | 30.62% |
| 2014 Q4 | 153.28 Million USD | 63.96% |
| 2014 Q3 | 93.48 Million USD | 100.6% |
| 2014 Q2 | 46.6 Million USD | -22.3% |
| 2014 Q1 | 59.97 Million USD | -25.64% |
| 2014 FY | 353.35 Million USD | 181.99% |
| 2013 FY | 125.3 Million USD | -17.15% |
| 2013 Q4 | 80.66 Million USD | 157.23% |
| 2013 Q3 | 31.35 Million USD | -12.6% |
| 2013 Q2 | 35.87 Million USD | 258.84% |
| 2013 Q1 | -22.58 Million USD | -131.41% |
| 2012 Q4 | 71.9 Million USD | 141.71% |
| 2012 Q1 | 26.2 Million USD | 123.57% |
| 2012 Q3 | 29.74 Million USD | 27.12% |
| 2012 FY | 151.25 Million USD | 74.6% |
| 2012 Q2 | 23.4 Million USD | -10.69% |
| 2011 Q2 | 30.62 Million USD | 26.86% |
| 2011 Q1 | 24.13 Million USD | -37.21% |
| 2011 FY | 86.62 Million USD | -30.64% |
| 2011 Q4 | 11.72 Million USD | -41.84% |
| 2011 Q3 | 20.15 Million USD | -34.19% |
| 2010 FY | 124.89 Million USD | 72.79% |
| 2010 Q2 | 29.79 Million USD | 40.49% |
| 2010 Q3 | 35.44 Million USD | 18.97% |
| 2010 Q1 | 21.2 Million USD | 81.19% |
| 2010 Q4 | 38.44 Million USD | 8.44% |
| 2009 FY | 72.28 Million USD | 43.2% |
| 2009 Q1 | 18.81 Million USD | -35.0% |
| 2009 Q2 | 24.68 Million USD | 31.24% |
| 2009 Q4 | 11.7 Million USD | -31.46% |
| 2009 Q3 | 17.07 Million USD | -30.83% |
| 2008 FY | 50.47 Million USD | 118.13% |
| 2008 Q4 | 28.93 Million USD | 497.08% |
| 2008 Q3 | -7.28 Million USD | -147.33% |
| 2008 Q2 | 15.39 Million USD | 14.67% |
| 2008 Q1 | 13.42 Million USD | 431.72% |
| 2007 Q2 | 9.26 Million USD | 103.11% |
| 2007 Q1 | -298.07 Million USD | -1838.86% |
| 2007 FY | -278.35 Million USD | -796.45% |
| 2007 Q4 | -4.04 Million USD | -127.91% |
| 2007 Q3 | 14.5 Million USD | 56.55% |
| 2006 Q4 | 17.14 Million USD | 6.06% |
| 2006 FY | 39.96 Million USD | 291.47% |
| 2006 Q1 | -104 Thousand USD | -131.9% |
| 2006 Q2 | 6.76 Million USD | 6607.69% |
| 2006 Q3 | 16.16 Million USD | 138.8% |
| 2005 FY | -20.87 Million USD | -235.33% |
| 2005 Q2 | -18.53 Million USD | -1401.13% |
| 2005 Q3 | -1.42 Million USD | 92.31% |
| 2005 Q4 | 326 Thousand USD | 122.86% |
| 2005 Q1 | -1.23 Million USD | -118.96% |
| 2004 Q2 | -3.51 Million USD | 18.4% |
| 2004 Q4 | 6.51 Million USD | 421.57% |
| 2004 Q3 | -2.02 Million USD | 42.38% |
| 2004 Q1 | -4.3 Million USD | 1.58% |
| 2004 FY | -6.22 Million USD | 77.0% |
| 2003 Q2 | -8.97 Million USD | 3.94% |
| 2003 Q3 | -5.51 Million USD | 38.56% |
| 2003 Q4 | -4.37 Million USD | 20.56% |
| 2003 Q1 | -9.33 Million USD | -16.73% |
| 2003 FY | -27.06 Million USD | 32.9% |
| 2002 Q2 | -31.84 Million USD | -267.45% |
| 2002 Q4 | -8 Million USD | -5.24% |
| 2002 Q3 | -7.6 Million USD | 76.13% |
| 2002 Q1 | -8.66 Million USD | -5.35% |
| 2002 FY | -40.33 Million USD | -62.47% |
| 2001 FY | -24.82 Million USD | -33.41% |
| 2001 Q3 | -5.78 Million USD | 1.83% |
| 2001 Q2 | -5.89 Million USD | -19.82% |
| 2001 Q1 | -4.91 Million USD | -6.53% |
| 2001 Q4 | -8.22 Million USD | -42.22% |
| 2000 Q3 | -3.87 Million USD | 26.47% |
| 2000 Q4 | -4.61 Million USD | -19.14% |
| 2000 Q1 | -4.84 Million USD | 0.0% |
| 2000 FY | -18.6 Million USD | -237.22% |
| 2000 Q2 | -5.26 Million USD | -8.74% |
| 1999 FY | -5.51 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | -399.37% |
| Prenetics Global Limited | -62.72 Million USD | -1750.97% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -74900.0% |
| CareDx, Inc | -190.28 Million USD | -510.141% |
| Exact Sciences Corporation | -204.14 Million USD | -468.702% |
| Exagen Inc. | -23.68 Million USD | -4801.009% |
| Inotiv, Inc. | -105.14 Million USD | -1004.242% |
| Guardant Health, Inc. | -479.44 Million USD | -142.153% |
| Biodesix, Inc. | -52.14 Million USD | -2126.441% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -44060.556% |
| Precipio, Inc. | -5.85 Million USD | -19735.982% |
| iSpecimen Inc. | -11.09 Million USD | -10359.942% |
| Natera, Inc. | -434.8 Million USD | -167.019% |
| Aspira Women's Health Inc. | -16.69 Million USD | -6856.261% |
| Standard BioTools Inc. | -74.65 Million USD | -1455.133% |
| 23andMe Holding Co. | -666.7 Million USD | -74.14% |
| Castle Biosciences, Inc. | -57.46 Million USD | -1920.325% |
| Personalis, Inc. | -108.29 Million USD | -972.062% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -1212.146% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -11571.792% |
| OpGen, Inc. | -32.66 Million USD | -3453.879% |
| T2 Biosystems, Inc. | -50.07 Million USD | -2218.43% |
| Myriad Genetics, Inc. | -112 Million USD | -936.607% |
| ICON Public Limited Company | 612.33 Million USD | 289.602% |
| NeoGenomics, Inc. | -87.96 Million USD | -1219.798% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -74900.0% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 237.39% |
| RadNet, Inc. | 3.04 Million USD | 38240.604% |
| MDxHealth SA | -43.1 Million USD | -2593.735% |
| Psychemedics Corporation | -4.15 Million USD | -27848.965% |
| Check-Cap Ltd. | -17.56 Million USD | -6508.607% |
| Twist Bioscience Corporation | -208.72 Million USD | -456.232% |
| DarioHealth Corp. | -59.42 Million USD | -1853.657% |
| Fulgent Genetics, Inc. | -167.82 Million USD | -591.792% |
| Sera Prognostics, Inc. | -36.24 Million USD | -3103.466% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -11440.469% |
| OPKO Health, Inc. | -188.86 Million USD | -514.731% |
| Medpace Holdings, Inc. | 282.81 Million USD | 510.523% |
| Neogen Corporation | -9.42 Million USD | -12223.533% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -11330.812% |
| Prenetics Global Limited | -62.72 Million USD | -1750.97% |
| Mainz Biomed B.V. | -26.29 Million USD | -4315.166% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -14527.673% |
| Trinity Biotech plc | -24.01 Million USD | -4733.875% |
| Neuronetics, Inc. | -30.18 Million USD | -3745.772% |
| Sotera Health Company | 51.37 Million USD | 2359.81% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -14527.673% |